A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma

• Georges Habineza Ndikuyeze,

  Affiliation Division of Hematology/Oncology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Anita Gaurnier-Hausser,

  Affiliation Office of Professional Studies in the Health Sciences, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America

  ⨯
• Reema Patel,

  Affiliation Antech Diagnostics, New Hyde Park, New York, United States of America

  ⨯
• Albert S. Baldwin,

  Affiliations TheraLogics, Inc., Chapel Hill, North Carolina, United States of America, Lineberger Comprehensive Cancer Center and Department of Biology, University of North Carolina, Chapel Hill, North Carolina, United States of America

  ⨯
• Michael J. May,

  Affiliation Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Patrick Flood,

  Affiliation 7-020G Katz Centre for Pharmacy and Health Research, The University of Alberta, Edmonton, Alberta, Canada

  ⨯
• Erika Krick,

  Affiliation Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯
• Kathleen J. Propert,

  Affiliation Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

  ⨯
• Nicola J. Mason

  * E-mail: nmason@vet.upenn.edu

  Affiliations Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

  ⨯